Nervous Disorder TRIZ Cases

Culturing proliferating oligodendrocyte progenitor cells with thyroid hormone ligands in low oxygen environments induces differentiation into adult OPC.

Apotransferrin induces a transition from T-helper 1 to T-helper 2 immunological profiles.

GABAA agents with restricted blood brain barrier permeability modulate dorsal root ganglion neurons to improve tactile sensitivity.

Targeting granins instead of beta-amyloid, compositions prevent toxic protein aggregation to treat Alzheimer's disease.

Membrane filtration separates Indian mulberry liquid into fractions, resolving insufficient duration by isolating effective high molecular weight components.

NAB61 antibody binds conformation-specific Aβ epitopes to neutralize toxic oligomers without cross-reacting with APP or C99.

Targeting conserved linear CD3 epsilon epitopes enables cross-species applicability while minimizing T cell redistribution and safety risks.

PPARγ agonists combined with opioid antagonists treat substance addiction by reducing consumption and preventing relapse despite poor conventional prognosis.

Substituted piperazine rings modify the chemical structure to increase brain uptake and reduce non-specific binding for improved imaging.

Lipoxin analogues activate GPR32 and FPR2/ALX receptors to protect retinal ganglion cells from degeneration.

Segmenting differentiation into three stages using specific cytokines achieves 100% purity, overcoming the low efficiency of conventional methods.

Anti-LPS enriched colostrum preparations neutralize lipopolysaccharides to prevent microbial translocation and reduce liver inflammation in chronic disease.

De-aerated vehicles saturated with NO gas prevent degradation of organic nitrites, ensuring stable therapeutic release.

Differentiated bone-forming cells express HLA class II molecules to treat immunodeficiency-related bone diseases without requiring IFNγ stimulation.

Antigen binding proteins deplete circulating serum amyloid P component by at least 90 percent, resolving toxicity and slow action of existing therapies.

Humanized antibodies use ENT transporters for cell penetration, reducing immunogenicity without losing DNA binding capability.

Intranasal C3a receptor agonists bypass systemic circulation to reduce adverse reactions while enhancing neural plasticity and reducing tissue loss.

Antibody-toxin conjugates target CD45 and CD117 markers to internalize cytotoxic payloads, depleting stem cells while sparing immune integrity.

Replacing Vero cells with immortalized HER cell suspension culture increases virus titers to 10^10/ml while eliminating microcarrier contamination.

Crystalline Form I achieves high purity and thermodynamic stability while maintaining low hygroscopicity through optimized phase transitions.

Attaching chorionic gonadotrophin carboxy-terminal peptides extends serum half-life and reduces dosing frequency.

Replacing mouse framework regions with human germline sequences reduces immunogenicity while maintaining binding affinity for treating inflammatory disorders.

Modified macrocyclic structures alter binding affinity to reduce adverse safety effects while maintaining therapeutic efficacy.

Merges PEG and magnesium into one formulation to reduce lesion size and chronic pain.

Salicylic acid derivatives serve as low-cost molecular chaperones that fold beta-glucocerebrosidase, overcoming the high expense of enzyme replacement therapy.

Restoring GDF11 levels treats age-related decline in neural stem cells by enhancing angiogenesis and cerebral blood flow.

Selective adenosine receptor modulators target multiple subtypes to realign the internal biological clock with external environmental cues.

Ganglioside-agglutinating agents cluster sialylated gangliosides, blocking amyloid-β interactions to reduce neuroinflammation and improve cognitive function.

Antioxidants mediate systemic cholinesterase inhibitor therapy to prevent adverse effects on non-target tissues while preserving therapeutic benefits.

Modular compounds resolve insufficient therapeutic efficacy for depression and schizophrenia by varying substituents to achieve broad-spectrum CNS activity.

Gene introduction of Oct3/4, Sox2, and Klf4 into postnatal tissue cells generates pluripotent stem cells that avoid immunological rejection.

Recombinant acid ceramidase hydrolyzes ceramide into sphingosine to enhance chondrogenic markers in cell cultures.

A Garcinia mangostana and Panax quinquefolius composition reduces neuronal cell death and increases neurite length.

Adenoviral vector expressing HSV-tk converts ganciclovir into cytotoxic metabolites to treat glioblastoma.

Isolated phytocannabinoids reduce mechanical and thermal hyperalgesia while minimizing side effects associated with opioid treatments.

An aminoacetonitrile compound inhibits cancer cell growth through specific structural formulations.

High-affinity antibodies block PAC1 receptors to reduce vasodilation, addressing poor tolerability of current migraine therapies.

Short dsRNA sequences selectively inhibit Nav1.8 expression, resolving the trade-off between pain relief efficacy and dose-limiting side effects.

Selective MKK7 inhibition modulates the JNK signaling pathway, improving therapeutic efficacy while minimizing systemic toxicity.

Microtube array membranes encapsulate therapeutic cells within ultra-thin polysulfone or PLGA-PLLA fibers to support nutrient diffusion.

Plasminogen activation degrades toxic protein aggregates, reducing cytotoxicity in neurodegenerative disease models.

Adhesive matrix dissolves donepezil using dicarboxylic acid esters and fatty acids to overcome poor skin permeability.

Star-shaped acrylic block polymers prevent drug precipitation and exudation in risperidone patches containing liquid solvents.

Stiripentol reduces hyperactivity via GABA enhancement, avoiding the dependency risks of methylphenidate.

Block copolymer nanoparticles self-assemble into core-shell structures to transport therapeutic polypeptides across biological barriers.